This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
Announcing the EAS Young Investigator Awards 2019

EAS is pleased to announce the winners of the annual Young Investigator Awards for outstanding publications during 2018. These annual EAS prizes for young scientists are intended to recognize distinction shown by publications that contribute to the advancement of knowledge in the field of atherosclerosis and linked metabolic disturbances.

Tom Seijkens, Amsterdam UMC, Amsterdam, The Netherlands - for the publication “Targeting CD40 induced TRAF6 signalling in macrophages reduces atherosclerosis” published in Journal of the American College of Cardiology (JACC).

J Am Coll Cardiol 2018 Feb 6;71(5):527-542.
DOI: 10.1016/j.jacc 2017.11.055.

Tom Seijkens studied Medicine at Maastricht University in the Netherlands, which he combined with cardiovascular research focused on the pathophysiology of atherosclerosis and the development of anti-inflammatory therapies for this disease. Tom obtained his PhD at the University of Amsterdam in 2014, under supervision of Prof. Dr. Esther Lutgens. In 2014 he started a residency in internal medicine at the Amsterdam University Medical Centers in Amsterdam.
Tom combines his clinical work with fundamental and translational research focused on the role of immune checkpoint proteins, especially CD40-CD40L, and the E3 ubiquitin ligase Cbl-b in atherosclerosis. As researcher and clinician it is his goal to translate fundamental cardiovascular research into innovative therapeutic strategies that improve the quality of life of patients with cardiovascular disease.


Antonio J. Vallejo-Vaz, Imperial Centre for Cardiovascular Disease Prevention Imperial College London, United Kingdom - for the publication “Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial” published in Circulation.

Circulation 2018;138(8):770-781.
DOI: 10.1161/CIRCULATIONAHA.117.032318

Dr Antonio J Vallejo-Vaz is Clinical Research Fellow at Imperial College London. He received his medical degree from the University of Seville, Spain, and later specialised in Internal Medicine in 2010. After working as a consultant in Internal Medicine and at a Unit of Vascular Risk, he went on to complete his PhD in Biomedical Research related to cardiovascular risk factors and endothelial dysfunction from the Institute of Biomedicine of Seville/University of Seville in 2016. He has been a fellow at the Cardiovascular and Cell Sciences Research Centre, St George´s University of London, before he moved to his current position at the Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, at Imperial College London.
Dr Vallejo-Vaz’s research focuses on atherosclerosis, vascular risk factors (mainly dyslipidaemias and hypertension) and cardiovascular disease prevention. It involves different epidemiological research projects, analysis from clinical trials, and evidence-synthesis studies, including the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC), an international initiative currently involving investigators form over 65 countries worldwide.

Membership Software Powered by YourMembership  ::  Legal